. 2015 Jun 20;24(5):470–476. doi: 10.1159/000431361

Table 2.

Effect of treatment with rivaroxaban on various tissue biomarkers from rats with TNBS-induced colitis

	Group 1 TNBS + R	Group 2 TNBS + MP	Group 3 TNBS	Group 4 controls
MPO, U/g	0.33 (0.25–0.47)^a	0.29 (0.25–0.32)^a,^b	0.47 (0.31–0.61)^d	0.17 (0.1–0.21)
MDA, μmol/g	3.9 (3.1–4.4)^a	3.6 (3.1–4.3)^a,^b	4.3 (3.1–5.5)^d	1.6 (1–2.8)
TGF-β₁, ng/g	2.3 (1–2.9)^{a, c}	4 (3–5.5)^a	5 (3.9–6.4)^d	1 (0.6–1.5)
MMP-3, ng/g	67 (28–86)^a,^c	128 (103–138)	124 (110–144)^d	33 (15–53)
TIMP-1, ng/g	11.3 (7.2–15.3)^a,^c	18.7 (10.5–28.2)	20.4 (17.1–24.4)^d	7.8 (6.5–10.9)
SOD, U/g	165 (160–169)^a,^c	158 (155–168)^a	142 (137–147)^d	159 (150–162)

MP = Methylprednisolone; R = rivaroxaban.

p < 0.05 compared with group 3.

p < 0.05 compared with group 1.

p < 0.05 compared with group 2.

p < 0.05 compared with group 4 for all parameters.